NASDAQ:EPIX ESSA Pharma (EPIX) Stock Price, News & Analysis $1.40 -3.80 (-73.08%) (As of 11/1/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About ESSA Pharma Stock (NASDAQ:EPIX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get ESSA Pharma alerts:Sign Up Key Stats Today's Range$1.40▼$1.6050-Day Range$1.40▼$7.1052-Week Range$1.40▼$11.67Volume34.23 million shsAverage Volume245,701 shsMarket Capitalization$62.12 millionP/E RatioN/ADividend YieldN/APrice Target$16.50Consensus RatingBuy Company OverviewESSA Pharma Inc., a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company's lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer. It has collaboration agreements with Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.Read More… Crypto Crash Ahead? (27 Experts Weigh In) (Ad)Your Portfolio Could Be at RISK Emergency summit reveals crypto could save you!Click here to reserve your spot at the emergency crypto summit now. ESSA Pharma Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks46th Percentile Overall ScoreEPIX MarketRank™: ESSA Pharma scored higher than 46% of companies evaluated by MarketBeat, and ranked 494th out of 975 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingESSA Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageESSA Pharma has received no research coverage in the past 90 days.Read more about ESSA Pharma's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for ESSA Pharma are expected to decrease in the coming year, from ($0.71) to ($0.97) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ESSA Pharma is -2.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ESSA Pharma is -2.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioESSA Pharma has a P/B Ratio of 0.42. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about ESSA Pharma's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted2.59% of the outstanding shares of ESSA Pharma have been sold short.Short Interest Ratio / Days to CoverESSA Pharma has a short interest ratio ("days to cover") of 19.5, which indicates bearish sentiment.Change versus previous monthShort interest in ESSA Pharma has recently increased by 2.68%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldESSA Pharma does not currently pay a dividend.Dividend GrowthESSA Pharma does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted2.59% of the outstanding shares of ESSA Pharma have been sold short.Short Interest Ratio / Days to CoverESSA Pharma has a short interest ratio ("days to cover") of 19.5, which indicates bearish sentiment.Change versus previous monthShort interest in ESSA Pharma has recently increased by 2.68%, indicating that investor sentiment is decreasing. News and Social Media0.9 / 5News Sentiment-0.34 News SentimentESSA Pharma has a news sentiment score of -0.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.41 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for ESSA Pharma this week, compared to 1 article on an average week.Search InterestOnly 2 people have searched for EPIX on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Company Ownership3.3 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, ESSA Pharma insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $20,903.00 in company stock.Percentage Held by Insiders14.70% of the stock of ESSA Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions75.12% of the stock of ESSA Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about ESSA Pharma's insider trading history. Receive EPIX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ESSA Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address EPIX Stock News HeadlinesEssa Pharma terminates Phase 2 study of masofaniten combo in mCRPCNovember 2 at 3:48 AM | markets.businessinsider.comEssa Pharma downgraded to Hold from Buy at JonesResearchNovember 1 at 10:47 PM | markets.businessinsider.com625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.November 2, 2024 | Crypto Swap Profits (Ad)Essa Pharma downgraded to Hold from Buy at JefferiesNovember 1 at 10:47 PM | markets.businessinsider.comEssa Pharma Shares Drop After Lead Drug Candidate FailsNovember 1 at 5:47 PM | marketwatch.comCancer-Focused ESSA Pharma Ends Prostate Cancer Trial Due to Insufficient Efficacy From Combination TherapyNovember 1 at 5:47 PM | benzinga.comESSA Pharma tanks after terminating trial for its prostate cancer treatmentNovember 1 at 5:47 PM | msn.comESSA Pharma Announces Termination of Phase 2 Study Evaluating Masofaniten Combined with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate CancerOctober 31 at 8:57 PM | prnewswire.comSee More Headlines EPIX Stock Analysis - Frequently Asked Questions How have EPIX shares performed this year? ESSA Pharma's stock was trading at $6.60 at the beginning of the year. Since then, EPIX shares have decreased by 78.8% and is now trading at $1.40. View the best growth stocks for 2024 here. How were ESSA Pharma's earnings last quarter? ESSA Pharma Inc. (NASDAQ:EPIX) issued its quarterly earnings data on Monday, August, 5th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.26) by $0.10. How do I buy shares of ESSA Pharma? Shares of EPIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of ESSA Pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that ESSA Pharma investors own include NVIDIA (NVDA), Broadcom (AVGO), Arista Networks (ANET), Meta Platforms (META), Jabil (JBL), Builders FirstSource (BLDR) and CymaBay Therapeutics (CBAY). Company Calendar Last Earnings8/05/2024Today11/02/2024Next Earnings (Estimated)12/10/2024Fiscal Year End9/30/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:EPIX CUSIPN/A CIK1633932 Webwww.essapharma.com Phone778-331-0962Fax604-738-4080Employees50Year FoundedN/APrice Target and Rating Average Stock Price Target$16.50 High Stock Price Target$17.00 Low Stock Price Target$16.00 Potential Upside/Downside+1,078.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.62) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-26,580,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-20.17% Return on Assets-19.62% Debt Debt-to-Equity RatioN/A Current Ratio36.95 Quick Ratio36.95 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.30 per share Price / Book0.42Miscellaneous Outstanding Shares44,369,000Free Float37,847,000Market Cap$62.12 million OptionableOptionable Beta1.83 Social Links 20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free Report This page (NASDAQ:EPIX) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…Crypto 101 Media | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredHow Will You Survive A Post Election Retirement Heist?The clock is ticking, and your life savings are in an extremely vulnerable position. We are a few days away...American Hartford Gold Group | SponsoredNvidia warning urgentI thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ESSA Pharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ESSA Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.